asxl1 C-terminal truncation and SRSF2 mutation drive leukemogenesis via immune reprogramming

Acute myeloid leukemia (AML) carrying mutations pertinent to chromatin-modification and spliceosome represents an aggressive subtype with poor prognosis.Specifically, mutations of genes encoding additional sex combs-like 1 (ASXL1), a member of the polycomb protein family [1, 2], and serine/arginine-rich splicing factor 2 (SRSF2), a member of RNA splicing machinery [3,4], are frequently found in myeloid neoplasms [5][6][7].The cooccurrence of ASXL1 and SRSF2 P95H mutations leads to a significantly worse prognosis than having either mutation alone, indicating a synergistic effect in leukemogenesis [1].Mice engineered with the Asxl1 C-terminal truncation and the Srsf2 P95H mutation developed leukemia characterized by a myeloid-biased hematopoietic stem cell (HSC) pool and a malignant transcriptomic signature [1].These findings correlate mutation combinations to leukemia progression, but the mechanisms driving leukemogenesis remain unclear, hindering targeted therapy development.Herein, we developed a zebrafish model carrying both mutations to gain new insights into the mechanisms underpinning the pathogenic synergism between asxl1 and SRSF2 P95H .By crossing zebrafish with a C-terminal truncation mutation in asxl1 [8] (referred to as "A") with Tg(Runx1: SRSF2 P95H ) (referred to as "S") transgenic zebrafish, which expresses the SRSF2 P95H mutation under the Runx1 promoter in the HSPC population [9] (Supplementary Fig. 1), we have generated a double mutant zebrafish model (referred to as "SA").At the embryonic stage, SA embryos showed a significant increase in myeloid progenitors, as shown by pu.1 expression, which was higher than asxl1 deletion or transgenic SRSF2 P95H alone (Fig. 1A,E).At 9-12 months, these double mutants exhibited an expanded monocytic compartment in their kidney marrow (KM), compared with the single mutants, as indicated by increased fluoride-sensitive NSE expression (Fig. 1B,F).Additionally, they exhibited higher KM blast

Authors

Institutions

Publication Details

Journal
Leukemia
Published
2025-11-03
DOI
https://doi.org/10.1038/s41375-025-02790-5
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

asxl1 C-terminal truncation and SRSF2 mutation drive leukemogenesis via immune reprogramming

Yiyue Zhang, Lingge Tu, David Liew, Chun-fung Sin et al.
Leukemia
Acute Myeloid Leukemia Research
article

asxl1 C-terminal truncation and SRSF2 mutation drive leukemogenesis via immune reprogramming

Yiyue Zhang, Lingge Tu, David Liew, Chun-fung Sin, Hong‐Lin Chan, Xuan Sun, Stephen Kwok‐Wing Tsui, Lichuan Zheng, Wenqing Zhang, Fangfang He, Alvin Chun Hang, Xinyu Miao, Anskar Y.H. Leung
article en

Abstract

Acute myeloid leukemia (AML) carrying mutations pertinent to chromatin-modification and spliceosome represents an aggressive subtype with poor prognosis.Specifically, mutations of genes encoding additional sex combs-like 1 (ASXL1), a member of the polycomb protein family [1, 2], and serine/arginine-rich splicing factor 2 (SRSF2), a member of RNA splicing machinery [3,4], are frequently found in myeloid neoplasms [5][6][7].The cooccurrence of ASXL1 and SRSF2 P95H mutations leads to a significantly worse prognosis than having either mutation alone, indicating a synergistic effect in leukemogenesis [1].Mice engineered with the Asxl1 C-terminal truncation and the Srsf2 P95H mutation developed leukemia characterized by a myeloid-biased hematopoietic stem cell (HSC) pool and a malignant transcriptomic signature [1].These findings correlate mutation combinations to leukemia progression, but the mechanisms driving leukemogenesis remain unclear, hindering targeted therapy development.Herein, we developed a zebrafish model carrying both mutations to gain new insights into the mechanisms underpinning the pathogenic synergism between asxl1 and SRSF2 P95H .By crossing zebrafish with a C-terminal truncation mutation in asxl1 [8] (referred to as "A") with Tg(Runx1: SRSF2 P95H ) (referred to as "S") transgenic zebrafish, which expresses the SRSF2 P95H mutation under the Runx1 promoter in the HSPC population [9] (Supplementary Fig. 1), we have generated a double mutant zebrafish model (referred to as "SA").At the embryonic stage, SA embryos showed a significant increase in myeloid progenitors, as shown by pu.1 expression, which was higher than asxl1 deletion or transgenic SRSF2 P95H alone (Fig. 1A,E).At 9-12 months, these double mutants exhibited an expanded monocytic compartment in their kidney marrow (KM), compared with the single mutants, as indicated by increased fluoride-sensitive NSE expression (Fig. 1B,F).Additionally, they exhibited higher KM blast

LeukemiaVol. 39(12)
Hong Kong Polytechnic University (HK), HSBC Holdings (GB), Queen Mary Hospital (CN), Hong Kong Science and Technology Parks Corporation (HK), Guangzhou First People's Hospital (CN), HKU-Pasteur Research Pole (HK), APT Electronics (China) (CN), University of Hong Kong (HK), South China University of Technology (CN), Guangzhou Medical University (CN)
National Natural Science Foundation of China, Innovation and Technology Commission, Hong Kong Government, Cornell Center for Materials Research, Health and Medical Research Fund
Openalex Percentile: Top 58%
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.